Keyphrases
Abatacept
19%
Adverse Cardiac Events
19%
AIDS/HIV
25%
Anti-spike Antibody
20%
Anti-spike Serology
19%
Antibiotic Choices
19%
Antiretroviral
19%
Antiretroviral Therapy
56%
Antiretroviral Therapy Regimens
18%
B Cell Response
38%
Bone Marrow Plasma Cells
24%
Cardiovascular Risk
19%
Cavernous Sinus Thrombosis
19%
Cenicriviroc
19%
COVID-19
22%
COVID-19 Pneumonia
19%
COVID-19 Severity
19%
Depressive Symptoms
19%
Germinal Center
25%
Germinal Center B Cells
20%
Germinal Center Reaction
36%
Incident Diabetes Mellitus
19%
Infliximab
19%
Influenza A
19%
Integrase Strand Transfer Inhibitor (INSTI)
55%
Intensive Care Unit
19%
Intracranial Thrombosis
19%
Long Peripheral Catheter
19%
Lymph Node
23%
Major Complications
19%
Management Strategy
19%
Memory B Cells
30%
Monoclonal Antibody
17%
MRNA Vaccine
34%
MSSA Bacteremia
19%
N Protein
19%
Obesity
19%
People Living with HIV (PLHIV)
100%
Placebo
16%
Randomized Clinical Trial
22%
Retrospective Review
19%
Risk Difference
19%
SARS-CoV-2 N Protein
19%
SARS-CoV-2 Omicron
19%
SARS-CoV-2 Spike Protein
21%
SARS-CoV-2 Vaccination
19%
Somatic Depressive Symptoms
19%
Somatic Hypermutation
15%
Temozolomide
19%
United States
19%
Medicine and Dentistry
Abatacept
19%
Antibiotics
29%
Antiinfective Agent
9%
Antiretroviral Therapy
21%
B Cell
24%
Bloodstream Infection
19%
Catheter Infection
19%
Cavernous Sinus Thrombosis
19%
Cenicriviroc
19%
Clinician
9%
COVID-19
41%
COVID-19 Vaccination
19%
Decision Making
19%
Deep Vein Thrombosis
19%
Diabetes Mellitus
19%
Disease Severity
19%
Diseases
9%
Epitope
7%
Gaze Paralysis
9%
Germinal Center
29%
Guanine Nucleotide Binding Protein
19%
Hazard Ratio
8%
Human Immunodeficiency Virus
77%
Hyperglycemia
11%
Immunomodulating Agent
5%
Infection
7%
Infliximab
19%
Influenza A
19%
Integrase
38%
Intensive Care Unit
29%
Internal Jugular Vein
9%
Lymph Node
19%
Memory B Cell
7%
Methicillin Susceptible Staphylococcus Aureus
19%
mRNA Vaccine
14%
Nasal Cannula
7%
Occlusive Cerebrovascular Disease
19%
Odds Ratio
8%
Omicron Coronavirus Variant
19%
Panton Valentine Leukocidin
9%
Placebo
19%
Randomized Clinical Trial
21%
Retrospective Study
19%
Sepsis
9%
Severe Acute Respiratory Syndrome Coronavirus 2
41%
Staphylococcal Bacteremia
9%
Staphylococcus Aureus
9%
Thrombophlebitis
9%
Thrombosis
9%